Pancreatic Cancer Research

ResearcherUniversity of MiamiNo recent work listed

Alice Nomura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1602-5950; OpenAlex author ID A5022134651. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper

Papers 11

  1. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Co-author DOI 10.1053/j.gastro.2020.09.010↗
  2. GRP78-mediated antioxidant response and ABC transporter activity confers chemoresistance to pancreatic cancer cells. Co-author DOI 10.1002/1878-0261.12322↗
  3. Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their lipid raft integrity. Co-author DOI 10.1016/j.canlet.2018.09.028↗
  4. Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters. First author DOI 10.1016/j.pan.2016.12.010↗
  5. Inhibition of Sp1 prevents ER homeostasis and causes cell death by lysosomal membrane permeabilization in pancreatic cancer. Co-author DOI 10.1038/s41598-017-01696-2↗
  6. Inhibition of hypoxic response decreases stemness and reduces tumorigenic signaling due to impaired assembly of HIF1 transcription complex in pancreatic cancer. Co-author DOI 10.1038/s41598-017-08447-3↗
  7. A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies. Co-author DOI 10.1007/s11605-015-2985-y↗
  8. Inhibition of NF-kappa B pathway leads to deregulation of epithelial-mesenchymal transition and neural invasion in pancreatic cancer. Co-author DOI 10.1038/labinvest.2016.109↗
  9. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0470-6↗
  10. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3228↗
  11. CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide. First author DOI 10.1158/1078-0432.ccr-13-2947↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sulagna Banerjee · 10 shared papers, 2014–2018 · strength 0.68
  2. Ashok Kumar Saluja · 10 shared papers, 2014–2018 · strength 0.68
  3. Vikas Dudeja · 9 shared papers, 2014–2018 · strength 0.58
  4. Patricia Dauer · 6 shared papers, 2016–2018 · strength 0.47
  5. Vineet Kumar Gupta · 4 shared papers, 2017–2018 · strength 0.30
  6. Nikita Sharma · 4 shared papers, 2017–2018 · strength 0.30
  7. Bhuwan Giri · 4 shared papers, 2016–2018 · strength 0.26
  8. Olivia McGinn · 3 shared papers, 2015–2017 · strength 0.20
  9. Rohit Chugh · 3 shared papers, 2014–2016 · strength 0.16
  10. Kaustav Majumder · 2 shared papers, 2016 · strength 0.12
  11. Selwyn Maurice Vickers · 2 shared papers, 2014–2015 · strength 0.10
  12. Katja Peschke · 1 shared paper, 2021 · strength 0.10
  13. Karin Feldmann · 1 shared paper, 2021 · strength 0.10
  14. Wilko Weichert · 1 shared paper, 2021 · strength 0.10
  15. H. Carlo Maurer · 1 shared paper, 2021 · strength 0.10
  16. Aristeidis Papargyriou · 1 shared paper, 2021 · strength 0.10
  17. Zahra Dantes · 1 shared paper, 2021 · strength 0.10
  18. Raphela A. Ranjan · 1 shared paper, 2021 · strength 0.10
  19. Maximilian Reichert · 1 shared paper, 2021 · strength 0.10
  20. Roland Michael Schmid · 1 shared paper, 2021 · strength 0.10
  21. Roland Rad · 1 shared paper, 2021 · strength 0.10
  22. Günter Schneider · 1 shared paper, 2021 · strength 0.10
  23. Anil K. Rustgi · 1 shared paper, 2021 · strength 0.10
  24. Dieter Saur · 1 shared paper, 2021 · strength 0.10
  25. Kousik Kesh · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.